References
- Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774–800
- Brabant G, Beck-Peccoz P, Jarzab B, et al. Is there a need to redefine the upper normal limit of TSH? Eur J Endocrinol 2006;154:633–7
- Celik C, Abali R, Tasdemir N, et al. Is subclinical hypothriodism contributing dyslipidemia and insulin resistance in women with polycystic ovary syndrome? Gynecol Endocrinol 2012;28:615–8
- Roos A, Bakker SJ, Links TP, et al. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. Clin Endocrinol Metab 2007;92:491–6
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25
- Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–9
- Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. Clin Endocrinol Metab 2004;89:2745–9
- Li Y, Fan P, Bai H, et al. The activity of platelet activating factor acetylhydrolase and its metabolic profile in patients with polycystic ovary syndrome. Sichuan Da Xue Xue Bao Yi Xue Ban 2009;40:1066–70
- Hong Y, Yang D, Liu W, et al. Dyslipidemia in relation to body mass index and insulin resistance in Chinese women with polycystic ovary syndrome. Biol Regul Homeost Agents 2011;25:365–74
- Costa EC, Soares EM, Lemos TM, et al. Central obesity index and cardiovascular risk factors in polycystic ovary syndrome. Arq Bras Cardiol 2010;94:633–8
- Verit FF. High sensitive serum C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome. Arch Gynecol Obstet 2010;281:1009–14
- Huang M, Xue J, et al. The relationship between homocysteine level and coronary atherosclerosis in patients with subclinical hypothyroidism. Chinese J Gerontol 2006;4:455–6
- Ochs N, Auer R, Bauer D, et al. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med 2008;148:832–45
- Taddei S, Caraccio N, Virdis A, et al. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism:benefical effect of levothyroxine therapy[J]. J Clin Endocrinol Metab 2003;88:3731–7
- Türemen EE, Çetinarslan B, Şahin T, et al. Endothelial dysfunction and low grade chronic inflammation in subclinical hypothyroidism due to autoimmune thyroiditis. Endocr J 2011;58:349–54
- Toruner F, Altinova AE, Karakoc A, et al. Risk factors for cardiovascular disease in patients with subclinical hypothyroidism. Adv Ther 2008;25:430–7
- Rezzonico J, Niepomniszcze H, Rezzonico M, et al. The association of insulin resistance with subclinical thyrotoxicosis. Thyroid 2011;21:945–9
- Frias Lopez MC, Torrage Lopez PJ, Rodriguez Montes JA, et al. Subclinical hypothyroidism and cardiovascular risk factors. Nutr Hosp 2011;26:1355–62
- Valentina VN, Marijan B, Chedo D, et al. Subclinical hypothyroidism and risk to carotid atherosclerosis. Arq Bras Endocrinol Metab 2011;55:475–80
- Ganie MA, Laway BA, Wani TA, et al. Association of subclinical hypothyroidism and phenotype, insulin resistance, and lipid parameters in young women with polycystic ovary syndrome. Fertil Steril 2011;95:2039–43